Page 718 - Clinical Hematology_ Theory _ Procedures ( PDFDrive )

702 PART 8 ■ Fundamentals of Hematological Analysis

REVIEW QUESTIONS (continued)

42. T e appropriate re erence value or iagnostic character- 45. Which o the ollowing is the appropriate re erence

istic o circulating anticoagulants is: value or f brin split pro ucts?

A. positive result: increase ratio o normal plasma to A. Normal: no issolution o the clot at 24 hours

patient plasma. B. Normal: less than 8 to 10 µg/mL

B. Normal: 2 to 8 minutes C. Normal: 50% to 150%

C. Normal: 20 to 35 secon s (28 to 42 secon s), the D. Normal: 200 to 400 mg/ L or a titer o 1:123 to 1:256

range epen ing on the activator an phospholipi

reagents 46. Which o the ollowing is the appropriate re erence

D. Normal: 80% to 100% (range, 107% ± 19%) value or f brin-stabilizing actor?

A. Normal: no issolution o the clot at 24 hours

43. T e appropriate re erence value or iagnostic character- B. Normal: less than 8 to 10 µg/mL

istic o the prothrombin time is: C. Normal: 50% to 150%

A. Normal 10 to 14 secon s D. Normal: 200 to 400 mg/ L or a titer o 1:123 to 1:256

B. Normal: 2 to 8 minutes

C. Normal: 20 to 35 secon s (28 to 42 secon s), the 47. Which o the ollowing is the appropriate re erence

range epen ing on the activator an phospholipi value or f brinogen assay?

reagents A. Normal: no issolution o the clot at 24 hours

D. Normal: 80% to 100% (range, 107% ± 19%) B. Normal: less than 8 to 10 µg/mL

C. Normal: 50% to 150%

44. Which o the ollowing is the appropriate re erence D. Normal: 200 to 400 mg/ L or a titer o 1:123 to 1:256

value or actor VIII assay?

A. Normal: no issolution o the clot at 24 hours

B. Normal: less than 8 to 10 µg/mL

C. Normal: 50% to 150%

D. Normal: 200 to 400 mg/ L or a titer o 1:123 to 1:256

COMPANION RES OURCES

http://thepoint.lww.com/ urgeon6e

Each stu ent is encourage to access an use the web-

base companion resources evelope or this chapter.

Here, you will f n a itional learning tools to increase

your un erstan ing o the concepts an clinical applica-

tions o the chapter.